Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: DR. MEADE who wrote (7326)	7/13/1998 11:35:00 AM
From: Logistics	Read Replies (1) \| Respond to of 8798

PBTK PBTK is a company that has a treatment for Multiple Sclerosis. I have noticed quiet accumulation of the stock. Latest news release shows that company is negotiating with a MAJOR pharmaceutical company. Spoke to company today and was told that news will be out shortly (was not given details regarding contents). I am posting the last release which shows that they are in negotiations and I took a position today: Wednesday June 17, 10:46 am Eastern Time Company Press Release SOURCE: Pathobiotek Diagnostics Inc. Pathobiotek Working on Licensing Agreement HOUSTON, June 17 /PRNewswire/ -- Pathobiotek Diagnostics Inc. (OTC Bulletin Board: PBTK - news) has entered into negotiations with a major pharmaceutical company for the purpose of licensing one of its diagnostic product applications. Further details are not available at this time. The resulting licensing agreement, if completed, would greatly enhance future revenue and profits. Pathobiotek has seventeen diagnostics under development and four of these are working prototypes. The Company is concentrating their efforts on the multiple sclerosis (MS) products and will continue to do so throughout 1998. Most of these products are used in conjunction with diagnosis and treatment of MS and CFS. One of the diagnostic tests measures the quantity of infectious organisms per unit of blood and provides information for the treating physician to interpret for the benefit of the patient. This product should go into clinical trials this year. Over the past five years, we have observed a 100% correlation between reduction of organism count and relief of symptoms of MS and CFS. Less than 30% MS samples tested responded to in-vitro sensitivities, but treatment success was somewhat better and is being improved continuously. SOURCE: Pathobiotek Diagnostics Inc. ------------------------------------------------------------------------ More Quotes and News:Pathobiotek Diagnostics Inc (OTC BB:PBTK - news)Related News Categories: medical/pharmaceutical